<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562287</url>
  </required_header>
  <id_info>
    <org_study_id>32356214200005327</org_study_id>
    <nct_id>NCT02562287</nct_id>
  </id_info>
  <brief_title>Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder</brief_title>
  <official_title>A Randomized Controlled Trial to Evaluate the Effectiveness of Clozapine Versus Olanzapine, Quetiapine or Risperidone in Treatment Resistant Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical use of clozapine has been an unequivocal advance in the treatment of&#xD;
      schizophrenia, a chronic and severe mental illness. A wealth of clinical data demonstrates it&#xD;
      offers enhanced efficacy on both positive and negative symptomatology, improving cognition,&#xD;
      functioning and quality of life. It is also associated with improved compliance and a&#xD;
      continued efficacy in long-term treatment that can be translated into a reduction of&#xD;
      suicidality and all-cause mortality. Because of preclinical evidence that it modulates&#xD;
      neuroplasticity and prefrontal cortex connectivity, clozapine may be an interesting strategy&#xD;
      for further severe psychotic illnesses. Nevertheless, even considering the growing use of&#xD;
      other atypical antipsychotics in the management of bipolar disorder, a role for clozapine has&#xD;
      been poorly defined. The clinical evidence-base for its use in this condition is largely&#xD;
      based on uncontrolled naturalistic trials and retrospective studies and chart reviews.&#xD;
      Several of these have supported clozapine's efficacy in treatment-resistant bipolar disorder.&#xD;
      Possibly because of clozapine's profile of adverse effects and lack of interest from&#xD;
      pharmaceutical companies, only two randomized trials have examined its effectiveness. Both&#xD;
      suggest clinically relevant antimanic and mood-stabilizing properties. Therefore, the primary&#xD;
      objective of this trial is to determine the effectiveness of clozapine for&#xD;
      treatment-resistant bipolar disorder. Secondary objectives include examining the effects of&#xD;
      treatment with clozapine on cognition and functioning of patients with bipolar disorder.&#xD;
      Tolerability and safety of long-term clozapine use will also be examined. To that end, the&#xD;
      investigators will conduct a clinical trial with 54 patients with a history of treatment&#xD;
      resistance. Patients will be randomized to either open-label treatment with clozapine, in&#xD;
      combination with lithium or valproate, or open-label treatment with an atypical antipsychotic&#xD;
      with consistent evidence of efficacy in the treatment of bipolar disorder (olanzapine,&#xD;
      quetiapine or risperidone), also in combination with lithium or valproate. Patients will be&#xD;
      followed for one-year and time to all-cause treatment failure will be the primary outcome&#xD;
      measure. It is the belief of the investigators that this study will generate meaningful&#xD;
      clinical data of tremendous importance to validate clozapine as a legitimate treatment option&#xD;
      for treatment-resistant bipolar disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functioning according to Functioning Assessment Short-Test</measure>
    <time_frame>6 month follow up</time_frame>
    <description>Global functioning according to Functioning Assessment Short-Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to all-cause treatment failure</measure>
    <time_frame>Six months</time_frame>
    <description>Include drug treatment (commencement of a new drug, restarting of a discontinued drug, or increasing the investigational drug dose in response to an emergent mood episode), admission to hospital or withdrawal from study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Clozapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clozapine, P.O., flexible dose, for up to 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone, olanzapine or quetiapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperidone, olanzapine or quetiapine, according to clinical indication, flexible dose, for up to 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>Flexible dosage, with up-titration according to standard schedules employed for schezophrenia</description>
    <arm_group_label>Clozapine</arm_group_label>
    <other_name>Clozaril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone, in a flexible dosage</description>
    <arm_group_label>Risperidone, olanzapine or quetiapine</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine, flexible dosage</description>
    <arm_group_label>Risperidone, olanzapine or quetiapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Quetiapine, flexible dosage</description>
    <arm_group_label>Risperidone, olanzapine or quetiapine</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-IV Bipolar I Disorder;&#xD;
&#xD;
          -  having had a mood episode within the preceding year; DSM-IV rapid cyclers will be&#xD;
             permitted to participate in this study;&#xD;
&#xD;
          -  males or females between 18 and 65 years of age;&#xD;
&#xD;
          -  ongoing illness symptoms including significant functional impairment;&#xD;
&#xD;
          -  documented history of treatment resistance, defined as persistent symptoms despite&#xD;
             simultaneous, adequate treatment with at least two medications: one mood stabilizer&#xD;
             (lithium or valproate) + antipsychotic OR two mood stabilizers (at least one of them&#xD;
             being lithium or valproate).&#xD;
&#xD;
          -  each patient must have a level of understanding sufficient to agree to all the tests&#xD;
             required by the protocol and must sign an informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with onset of illness after age 40 or illness resulting from secondary causes&#xD;
&#xD;
          -  women who are pregnant or breastfeeding, or not using adequate contraception&#xD;
&#xD;
          -  unstable medical illnesses&#xD;
&#xD;
          -  clinically significant abnormal laboratory tests&#xD;
&#xD;
          -  current active alcohol or substance abuse&#xD;
&#xD;
          -  severe personality disorders&#xD;
&#xD;
          -  contraindication to the use of clozapine or previous treatment with clozapine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PEDRO V MAGALHAES, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre / Universidade Federal do Rio Grande do Sul</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PEDRO V MAGALHAES, M.D., Ph.D.</last_name>
    <phone>+555191123773</phone>
    <email>pedromaga2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90540001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PEDRO V MAGALHAES, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Pedro Vieira da Silva Magalhães</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

